CDK7 and small cell lung carcinoma: A selective CDK7 inhibitor, YKL-5-12, was tested in association with anti-topoisomerase I, topotecan and ICIs, revealing that CDK7 inhibition predominately destroy cell-cycle progression and induces DNA replication stress and genomic instability in SCLC cells, promoting also immuno-response signalling.